Larazotide vs Thymosin Alpha-1
Overview
Larazotide and Thymosin Alpha-1 are both healing & recovery peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Larazotide and Thymosin Alpha-1 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Larazotide | Thymosin Alpha-1 | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Regulatory status (US) | Research use only | Research use only |
| Typical dosage | 1-8 mg | 1.6-3.2 mg |
| Frequency | three times daily | twice-weekly |
| Reported benefits | Reduces intestinal permeability, improves gut barrier function, celiac disease support | Immune enhancement, antiviral properties, chronic infection support, cancer therapy adjunct |
| Reported side effects | Generally well-tolerated, possible headache | Well-tolerated. Rare: injection site reactions, mild flu-like symptoms |
Key differences
Primary use. Larazotide is categorised under Healing & Recovery, while Thymosin Alpha-1 falls under Healing & Recovery. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Larazotide: not FDA-approved; treated as a research compound. Thymosin Alpha-1: not FDA-approved; treated as a research compound.
Dosing. Larazotide is typically dosed at 1-8 mg (three times daily). Thymosin Alpha-1 is typically dosed at 1.6-3.2 mg (twice-weekly).
Can you stack them?
Some protocols combine peptides, but stacking Larazotide and Thymosin Alpha-1 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Larazotide and Thymosin Alpha-1?
- Larazotide and Thymosin Alpha-1 are both healing & recovery peptides, but they differ in mechanism, dosing, and regulatory status. Larazotide is not FDA-approved; generally classified as a research compound, whereas Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
- What is Larazotide used for?
- Gut permeability regulator.
- What is Thymosin Alpha-1 used for?
- Immune system support.
- Can you take Larazotide and Thymosin Alpha-1 together?
- Some users combine peptides within a single protocol, but stacking Larazotide and Thymosin Alpha-1 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Larazotide or Thymosin Alpha-1 FDA-approved?
- Larazotide is not FDA-approved; generally classified as a research compound. Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
Read the full articles
- Larazotide — full monograph: mechanism, research, dosing & references
- Thymosin Alpha-1 — full monograph: mechanism, research, dosing & references